Back to Search
Start Over
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
- Source :
-
The Canadian journal of cardiology [Can J Cardiol] 2018 Mar; Vol. 34 (3), pp. 337-341. Date of Electronic Publication: 2017 Dec 07. - Publication Year :
- 2018
-
Abstract
- Atrial fibrillation is a side effect of ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase used for treatment of B-cell lymphoproliferative disorders. We determined if single (2 or 10 mg/kg), or chronic (14 days) oral ibrutinib followed by 24-hour washout conferred susceptibility to electrically induced arrhythmias in 1-month-old male C57BL/6 mice. A single higher dose of ibrutinib increased arrhythmia inducibility. There was no inducibility difference after chronic dosing with washout. This suggests that high serum drug levels might be responsible for the proarrhythmic effect of ibrutinib and that an altered dosing strategy might mitigate the side effects.<br /> (Copyright © 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adenine analogs & derivatives
Animals
Atrial Fibrillation diagnostic imaging
Atrial Fibrillation epidemiology
Disease Models, Animal
Dose-Response Relationship, Drug
Electrocardiography methods
Male
Mice
Mice, Inbred C57BL
Piperidines
Pyrazoles administration & dosage
Pyrimidines administration & dosage
Random Allocation
Reference Values
Risk Assessment
Ventricular Fibrillation diagnostic imaging
Ventricular Fibrillation epidemiology
Atrial Fibrillation chemically induced
Disease Susceptibility epidemiology
Pulse Therapy, Drug methods
Pyrazoles adverse effects
Pyrimidines adverse effects
Ventricular Fibrillation chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 1916-7075
- Volume :
- 34
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The Canadian journal of cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 29475534
- Full Text :
- https://doi.org/10.1016/j.cjca.2017.12.001